Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.59 USD
+0.10 (2.87%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $3.58 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
RPTX 3.59 +0.10(2.87%)
Will RPTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RPTX
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
Other News for RPTX
Repare Therapeutics Reports Q3 2024 Progress and Outlook
Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating with $10 Price Target
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Repare Therapeutics reports Q3 EPS (81c), consensus (83c)
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes